Quanterix (NASDAQ:QTRX) Issues Earnings Results

Quanterix (NASDAQ:QTRX) released its quarterly earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04), FiscalAI reports. Quanterix had a negative net margin of 80.25% and a negative return on equity of 26.09%. The company had revenue of $34.97 million during the quarter, compared to analyst estimates of $33.85 million.

Here are the key takeaways from Quanterix’s conference call:

• Q3 revenue was $35 million, up 6.3% sequentially but down 13.1% year over year (8.6% on a pro forma basis). Quanterix narrowed its 2026 revenue outlook to $142 million–$146 million and expects a stronger Q4, while noting the commercial changes will have a larger impact in 2027.
• Spatial revenue grew by a double-digit percentage sequentially, with consumables reaching their second-highest level ever. Accelerator Lab bookings improved for a second consecutive quarter, with book-to-bill approaching 2x.
• LucentAD Complete test volume more than doubled sequentially, and new lab partnerships are expected to expand its reach. Florida Medicaid coverage took effect at a reimbursement rate of $484 per test for eligible residents, though diagnostic revenue remains relatively small and FDA timing is uncertain.
• Cash usage was $16.2 million in Q3, leaving $80.7 million on hand; the company expects to end 2026 with about $70 million and no debt. Management reiterated its cash-flow breakeven target for 2027, after moving that goal out from 2026.

Quanterix Trading Down 1.2%

NASDAQ QTRX traded down $0.04 during trading on Tuesday, reaching $3.34. 241,311 shares of the company’s stock were exchanged, compared to its average volume of 855,665. Quanterix has a fifty-two week low of $2.15 and a fifty-two week high of $8.77. The company’s fifty day simple moving average is $3.01 and its 200-day simple moving average is $3.78. The firm has a market capitalization of $158.00 million, a PE ratio of -1.27 and a beta of 1.06.

Analysts Set New Price Targets

QTRX has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quanterix in a research note on Wednesday, November 4th. Canaccord Genuity Group cut their price objective on shares of Quanterix from $4.00 to $3.00 and set a “hold” rating for the company in a research report on Monday, August 17th. TD Cowen upped their target price on shares of Quanterix from $3.00 to $3.50 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Finally, Wall Street Zen lowered Quanterix from a “hold” rating to a “sell” rating in a research note on Saturday. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $3.25.

Quanterix Company Profile

Quanterix Corporation (NASDAQ:QTRX) is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other molecules at very low concentrations, supporting research into disease biology, diagnosis, treatment response and drug development.

The company’s principal technology, Simoa, uses digital detection methods to improve the sensitivity of immunoassays.